The company will use the funds to pursue its vision of identifying unmet medical needs that are unique to women, addressing them with scientific rigor, and providing answers that have an immediate, positive impact on their lives. The company will use a broad and deep scientific approach to test development, focusing initially on gynecological cancers.

The financing was co-led by Catalio Capital Management, LP, and The Production Board. Other investors include Mountain Group Partners, Byers Capital and Mayo Clinic.

PinkDx is an early-stage company focused on addressing the medical problems that women uniquely face by applying sophisticated scientific approaches to resolve them and providing answers that have an immediate, positive impact on their lives. The company's first indication will focus on overcoming diagnostic challenges for women who present with general symptoms that could signal a gynecological cancer.